hb0045
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2023 (NCT06056323)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5'-nucleotidaseINHIBITOR
NT5E inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06056323 | Phase 1/Phase 2 (Phase 2) | Jul 18, 2023 | Gabrail Cancer Center, Harvard University, University of Texas at Houston, Zhejiang Huahai Pharmaceutical Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1